Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the ‘Use Via Early Access to Ixazomib’ (UVEA-IXA) Study

Heinz Ludwig,Evangelos Terpos,María-Victoria Mateos,Mario Boccadoro,Bhuvan Kishore,Karthik Ramasamy,Sylvie Fernandez,Fabio Ferri,Nawal Bent-Ennakhil,Athanasios Zomas,François Gavini,Roman Hajek

doi:10.1182/blood-2020-136519

Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the ‘Use Via Early Access to Ixazomib’ (UVEA-IXA) Study

Heinz Ludwig, Evangelos Terpos + Show 10 more

Open Access

https://doi.org/10.1182/blood-2020-136519

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 6

Affiliation: National and Kapodistrian University of Athens, Centro de Investigación del Cáncer, Instituto de Investigación Biomédica de Salamanca, University of Turin, University Hospitals Birmingham NHS Foundation Trust, University of Oxford, Takeda (Switzerland), University Hospital Ostrava

#Advisory Committees #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the ‘Use Via Early Access to Ixazomib’ (UVEA-IXA) Study

Full Text